Table 1—

Estimated number of dispensed outpatient prescriptions (in millions) for oral antidiabetic drugs in the U.S. in 1990, 1996, and 2001

Generic nameTrade nameDate marketed199019962001
Sulfonylureas
 TolbutamideOrinase19570.8 (3)0.2 (<1)0.08 (<1)
 ChlorpropamideDiabinese, glucamide19583.2 (14)1.1 (3)0.3 (<1)
 AcetohexamideDymelor19640.2 (1)0.02 (<1)0.006 (<1)
 TolazamideTolinase19661.1 (5)0.3 (1)0.1 (<1)
 GlipizideGlucotrol, glucotrol XL19845.1 (22)11.6 (28)17.9 (19.5)
 GlyburideDiabeta, micronase, glynase198413.0 (55)19.3 (47)14.7 (16.0)
 GlimepirideAmaryl19960.2 (<1)6.1 (6.7)
Biguanide
 MetforminGlucophage19957.8 (19)30.0 (32.7)
Combination*
 Glyburide-metforminGlucovance20004.5 (4.9)
Glucosidase inhibitors
 AcarbosePrecose19950.5 (1)0.5 (0.5)
 MiglitolGlyset19990.2 (0.2)
Nonsulfonylurea insulin secretagogues
 RepaglinidePrandin19981.4 (1.5)
 NateglinideStarlix20010.5 (0.5)
Thiazolidinedione insulin sensitizers
 TroglitazoneRezulin1997
 RosiglitazoneAvandia19998.2 (8.9)
 PioglitazoneActos19997.2 (7.9)
Total23.441.091.7
  • Data are n (%). Source: IMS Health, National Prescription Audit Plus, Plymouth Meeting, PA, extracted June 2002.

  • *

    * Combination sulfonylurea and biguanide;

  • 14 million dispensed outpatient prescriptions from the start of marketing in 1997 until withdrawal due to hepatotoxicity in 2000.